Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6721 to 6735 of 7700 results

  1. Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

    Discontinued [GID-TA10767]

    Technology appraisal guidance
    Discontinued

  2. Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]

    Discontinued [GID-TA11208]

    Technology appraisal guidance
    Discontinued

  3. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued [GID-TA10074]

    Technology appraisal guidance
    Discontinued

  4. Prostate cancer (hormone relapsed, metastatic) - rilimogene galvacirepvec (with rilimogene glafolivec, chemotherapy-naive) [ID1018]

    Discontinued [GID-TA11177]

    Technology appraisal guidance
    Discontinued

  5. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued [GID-TA11178]

    Technology appraisal guidance
    Discontinued

  6. Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

    Discontinued [GID-TA10210]

    Technology appraisal guidance
    Discontinued

  7. Intravaginal sling for stress urinary incontinence

    Discontinued [GID-IP267]

    Interventional procedures guidance
    Discontinued

  8. Extra corporeal membrane oxygenation for acute heart failure in children

    Discontinued [GID-IP1153]

    Interventional procedures guidance
    Discontinued

  9. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued [GID-TA11179]

    Technology appraisal guidance
    Discontinued

  10. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued [GID-TA11120]

    Technology appraisal guidance
    Discontinued

  11. Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]

    Discontinued [GID-TA10356]

    Technology appraisal guidance
    Discontinued

  12. Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

    Discontinued [GID-TA10474]

    Technology appraisal guidance
    Discontinued

  13. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued [GID-TA10437]

    Technology appraisal guidance
    Discontinued

  14. Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy [ID1147]

    Discontinued [GID-TA10343]

    Technology appraisal guidance
    Discontinued

  15. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

    Discontinued [GID-TA10473]

    Technology appraisal guidance
    Discontinued